If medicine could really slow down human aging, the first problem might not be health-related, but financial.
Ask the Sun
The questions are automatically suggested by 24Ore AI
based on the content viewed.
It is one of the most provocative reflections that emerged from Longevity 21, the international conference dedicated to longevity and mortality risks held this week at La Sapienza University of Rome in collaboration with the Bayes Business School of City University London.
For decades, life extension has been considered an indicator of progress. Today, however, a growing part of the financial sector is questioning the economic consequences of this demographic transformation: for pensions, insurance, and public finances, living longer also means having to sustain financial commitments for much longer periods.
Read more 2027 Budget, proposals for young people: flat tax, tax incentives, academic merit income
And what if the increase in life expectancy were not gradual but sudden? This is the question posed by Guy Coughlan, Chief Operating Officer of Clota Varde, member of the Advisory Board of Longitude Solutions, and non-executive director of J.P. Morgan Pension Trustees. Coughlan urged the sector to prepare for a scenario that until a few years ago would have been considered science fiction: the arrival of therapies capable of significantly modifying the biological aging process.
According to the scenario presented at the conference, a combination of artificial intelligence applied to pharmaceutical research, new biological knowledge, and repurposing of existing drugs could increase the life expectancy of a sixty-five-year-old by about ten years and that of a forty-year-old by almost twenty years. The consequence, Coughlan explained, would be immediate: “Longevity risk will be reassessed by the markets even before people actually start living longer.”
Read more Virtuous behaviors, green homes, and higher temperatures: this winter we will save 1.2 …
